🌏 中文版
Funding details
| Item | Value |
|---|---|
| Company | Confido Health (US, New York) |
| Round | Series A (extension) |
| Amount | $12.5M (extension, closed February 2026, announced in October) |
| Lead | Z47 (formerly Matrix Partners India) |
| Participants | Together Fund, Blume Ventures, Justin Saks (healthcare PE veteran, joining as a board advisor) |
| Valuation | Undisclosed |
| Total raised | $22.5M ($10M Series A in September 2025 + this $12.5M extension) |
| Founded | 2022 |
| Headcount | Undisclosed |
What the company does
Confido Health builds AI agents that handle the administrative side of running a medical practice — not writing clinical notes, but answering phones, scheduling visits, verifying insurance, and chasing payments: the back-office work nobody wants to do but that a practice can't survive without.
Its product, CareOS, is pitched as a "system of action" rather than a "system of record." It plugs directly into a practice's existing 50-plus systems — EHRs, scheduling, phone systems, billing, fax — without requiring the practice to switch tools, then executes the work itself: a single interaction can trigger a referral, an appointment, a prescription refill, and a payment collection, instead of routing each step to a different tool or person. Confido claims a 95%-plus AI handle rate across core workflows, and says practices gain capacity equivalent to 3-5 full-time staff within three months of deployment, with projected annual savings of $10-15M per provider group.
Confido now runs across more than 1,500 care sites in 27 states, reaching roughly 3,200 providers, concentrated in ophthalmology/optometry, physical therapy, dental, and primary/community care. The company says it has grown 15x since its last round.
What this round signals
What it means for the agent ecosystem
Confido's growth engine isn't conventional B2B sales — it's treating private equity funds as a distribution channel. Roughly a third of specialty care in the US is now run by PE-backed provider groups, and those funds' AI evaluation teams tend to pilot Confido at one portfolio company, then push it across every other practice the fund holds once ROI is proven. One signed deal can open the door to an entire portfolio's worth of customers. In a fragmented, heavily regulated, understaffed vertical, that's a faster distribution path than signing clinics one by one: lock in the capital owner, not just the end customer.
What investors are betting on
Z47 partner Vikram Vaidyanathan put it bluntly: "Healthcare administration is a trillion-dollar cost center, and for decades the only way to manage it was to hire more people." That framing positions Confido as a substitute for healthcare labor, not just another piece of software. The healthcare-agent subsector is unusually crowded this same stretch — EliseAI landed $350M in September (at a $4B valuation), Heidi raised $340M, Suki AI just closed a $90M Series E, Assort Health took $120M in a June Series C, and Artera raised $65M in December — all betting on the same "agents replace labor" narrative. Confido's differentiation is picking a battlefield — PE-owned, multi-site practices — rather than competing head-on with those rivals for independent hospitals or chains.
Numbers worth watching
- At $22.5M total raised, Confido is an order of magnitude behind peers like EliseAI ($350M) and Heidi ($340M) announced the same week, but its 15x growth rate is the standout figure in this cohort — less capital, faster growth, which says the distribution strategy matters more than round size.
- A 95% AI handle rate translated directly into "3-5 full-time-equivalent" capacity gains is a rare case of an agent company converting efficiency into a headcount-cost number buyers can run ROI math on, rather than a vague "saves time" claim.
- Coverage across 27 states and 3,200 providers works out to roughly 1 in 50 Americans now able to reach a provider through a Confido agent — a user base well out of proportion to a company that's raised only $22.5M since founding in 2022.
Watchlist status
Confido Health isn't on the watchlist yet. Recommend adding it to section D5 (currently Abridge, Ambience Healthcare, Hippocratic AI, and Suki AI, focused on clinical/healthcare agents), tracking: administrative healthcare agents (distinct from D5's current clinical-documentation focus), go-to-market through private-equity portfolios, and 15x YoY growth.
Takeaway
Confido is a reminder that in fragmented, regulated industries, an agent company's distribution strategy can be more interesting than its product — instead of convincing every clinic one at a time, convince the private equity funds that own the clinics' equity, and let the capital structure itself become the sales channel.